Increasing ApoA1 in the brain is being investigated to normalize cholesterol synthesis and removal, and reduce inflammation in ApoE4 carriers.

“we are doing a proof of concept trial where we tap cerebrospinal fluid and we look at I mean like 50 biomarkers because what we hope is that Apple A1 goes up in the brain that the consequence of that is that the cells are going to normally synthesize cholesterol so the desmosterol and latosterol levels should go up because cholesterol synthesis is normalized again at the same time 24 hydroxy cholesterol should also go up because cells are getting rid of cholesterol in a normal fashion and the inflammation biomarker should go down because you basically substitute for this dysfunctional E4”